


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | |
|--|---|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | Complete if Known | |
| Date Submitted: November 4, 2008 (use as many sheets as necessary) | | | Application Number | 10/031,145 |
| | | | Filing Date | 8/10/2000 |
| | | | First Named Inventor | Nicole Zitzmann |
| | | | Art Unit | 1617 |
| | | | Examiner Name | Kathrien Ann Cruz |
| Sheet | 1 | of | 6 | Attorney Docket Number |
| 080618-0241 | | | | |



U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|--|--------------------------------|--|--|
| | | Number-Kind Code ² (if known) | | | |
| K.C./ | A1 | 2006/0106065 A1 | 05/18/2006 | Jacob et al. | |
| | A2 | 2006/0252918 A1 | 11/20/2006 | Rowlands et al. | |
| | A3 | 2006/0264468 A1 | 11/23/2006 | Mueller et al. | |
| | A4 | 2006/0094671 A1 | 05/04/2006 | Jacob et al. | |
| | A5 | 4,246,345 | 01/20/1981 | Kinast et al. | |
| | A6 | 4,266,025 | 05/05/1981 | Kinast et al. | |
| | A7 | 4,405,714 | 09/20/1983 | Kinast et al. | |
| | A8 | 4,806,650 | 02/21/1989 | Schröder et al. | |
| | A9 | 4,861,892 | 08/29/1989 | Fleet | |
| | A10 | 4,894,388 | 01/16/1990 | Fleet | |
| | A11 | 4,910,310 | 03/20/1990 | Campbell et al. | |
| | A12 | 4,944,572 | 07/31/1990 | Young | |
| | A13 | 4,996,329 | 02/26/1991 | Fleet et al. | |
| | A14 | 5,011,929 | 04/30/1991 | Fleet et al. | |
| | A15 | 5,013,842 | 05/07/1991 | Fleet et al. | |
| | A16 | 5,017,704 | 05/21/1991 | Fleet et al. | |
| | A17 | 5,043,273 | 08/27/1991 | Scudder et al. | |
| | A18 | 5,100,797 | 03/31/1992 | Fleet et al. | |
| | A19 | 5,103,008 A | 04/07/1992 | Scudder et al. | |
| | A20 | 5,200,523 | 04/06/1993 | Fleet | |
| | A21 | 5,264,356 A | 11/23/1993 | Rohrschneider | |
| | A22 | 5,286,877 | 02/15/1994 | Behling et al. | |
| | A23 | 5,310,745 | 05/10/1994 | Partis et al. | |
| | A24 | 5,401,645 A | 03/28/1995 | Grabner et al. | |
| | A25 | 5,580,884 | 12/03/1996 | Platt et al. | |
| | A26 | 5,596,005 A | 01/21/1997 | Wong et al. | |
| | A27 | 5,622,972 | 04/22/1997 | Bryant et al. | |
| | A28 | 5,643,888 A | 07/01/1997 | Rohrschneider | |
| | A29 | 5,291,657 B1 | 09/18/2001 | Platt et al. | |
| | A30 | 6,355,413 B1 | 03/12/2002 | Gage et al. | |
| | A31 | 6,465,487 B1 | 10/15/2002 | Block et al. | |
| | A32 | 6,465,488 B1 | 10/15/2002 | Butters et al. | |
| | A33 | 6,545,021 B1 | 04/08/2003 | Mueller et al. | |
| | A34 | 6,660,749 B2 | 12/09/2003 | Butters et al. | |
| | A35 | 6,689,759 B1 | 02/10/2004 | Jacob et al. | |
| | A36 | 6,809,083 B1 | 10/26/2004 | Mueller et al. | |

| | | | |
|--------------------|-----------------|-----------------|------------|
| Examiner Signature | /Kathrien Cruz/ | Date Considered | 03/26/2009 |
|--------------------|-----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov/patent/mpep/001.04_3.html. 3 Entry Office that issued the document, by its two-letter code (WIPO Standard ST.16 if applicable).

Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: November 4, 2008

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/031,145 |
| Filing Date | 8/10/2000 |
| First Named Inventor | Nicole Zitzmann |
| Art Unit | 1617 |
| Examiner Name | Kathrien Ann Cruz |
| Attorney Docket Number | 080618-0241 |

Sheet

2

of

6

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

| Examiner Initials* | Cite No. ¹ | U.S. Patent Application Document Serial Number-Kind Code ² (if known) | Filing Date of Cited Document MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|--|--|--|--|----------------|
| /K.C./ | A37 | EP 0 367 747 A | 05/09/1990 | G.D. Searle & Company | | |
| | A38 | EP 0 445 098 A2 | 02/25/1991 | G.D. Searle & Company | | |
| | A39 | WO 98/35685 A1 | 08/20/1998 | G.D. Searle & Company | | |
| | A40 | WO 99/24401 A1 | 05/20/1999 | G.D. Searle & Company | | |
| | A41 | WO 99/40916 A1 | 08/19/1999 | G.D. Searle & Co. | | |
| | A42 | WO 00/47198 A2 | 08/17/2000 | G.D. Searle & Company | | |
| | A43 | WO 01/60366 A1 | 08/23/2001 | Pharmacia Corporation | | |
| V | A44 | WO 2004/00533 A1 | 01/15/2004 | University of Leeds | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ⁴ "Number" Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Documents | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|--|--------------------------------|---|--|----------------|
| /K.C./ | A37 | EP 0 367 747 A | 05/09/1990 | G.D. Searle & Company | | |
| | A38 | EP 0 445 098 A2 | 02/25/1991 | G.D. Searle & Company | | |
| | A39 | WO 98/35685 A1 | 08/20/1998 | G.D. Searle & Company | | |
| | A40 | WO 99/24401 A1 | 05/20/1999 | G.D. Searle & Company | | |
| | A41 | WO 99/40916 A1 | 08/19/1999 | G.D. Searle & Co. | | |
| | A42 | WO 00/47198 A2 | 08/17/2000 | G.D. Searle & Company | | |
| | A43 | WO 01/60366 A1 | 08/23/2001 | Pharmacia Corporation | | |
| V | A44 | WO 2004/00533 A1 | 01/15/2004 | University of Leeds | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|---|----------------|
| /K.C./ | A45 | ACOSTA et al., "Agents for treating human immunodeficiency virus infection," Am. J. Hosp. Pharm., September 15, 1994, 51:2251-2267. | |
| | A46 | BERGE et al., "Pharmaceutical Salts," J. Pharm. Sci., January 1977, 66(1):1-19. | |
| | A47 | BERGERON et al., "Calnexin: a membrane-bound chaperone of the endoplasmic reticulum," TIBS 19 - March 1994, Elsevier Scient Ltd. 0968-0004/94 pp. 124-128. | |
| | A48 | BLOCK et al., "Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin," PNAS, March 1994, 91:2235-2239. | |
| V | A49 | BLUM et al., "Antiviral therapy of hepatitis B virus infection: Blocking viral gene expression," Advanced Drug Delivery Reviews, 1995, 17:321-331. | |

| | | | |
|--------------------|-----------------|-----------------|------------|
| Examiner Signature | /Kathrien Cruz/ | Date Considered | 03/26/2009 |
|--------------------|-----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO patent documents at www.uspto.gov or MPEP 611.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, indicate the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: November 4, 2008
(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/031,145 |
| Filing Date | 8/10/2000 |
| First Named Inventor | Nicole Zitzmann |
| Art Unit | 1617 |
| Examiner Name | Kathrien Ann Cruz |
| Attorney Docket Number | 080618-0241 |

Sheet

3

of

6

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|---|----------------|
| K.C.J. | A50 | BRANZA-NICHITA et al., "Antiviral of N-Butyledeoxyxojirimycin against Bovine Viral Diarrhea Virus. Coorelates with Misfolding of E2 Envelope Proteins and Impairment of Their Association into E1-E2 Heterodimers," (2001) J. Virol. 75(8), pp. 3527-36. | |
| | A51 | BRUSS et al., "The role of envelope proteins in hepatitis B virus assembly, PNAS, February 1991, 88:1059-1063. | |
| | A52 | CARRÈRE-KREMER et al., "Subcellular Localization and Topology of the p7 Polypeptide of Hepatitis C Virus," Journal of Virology, April 2002, 76(8): 3720-3730. | |
| | A53 | CHOUKHI et al., "Involvement of Endoplasmic Reticulum Chaperones in the Folding of Hepatitis C Virus Glycoproteins, (1998) J. Virol., 72(5), pp. 3851-8. | |
| | A54 | COATES et al., "Developments in viral hepatitis during 1994," Exp. Opin. Ther. Patents, 1995, 5(8):747-756. | |
| | A55 | COURAGEOT et al., "α-Glucosidase Inhibitors Reduce Dengue Virus Production by Affecting the Initial Steps of Virion Morphogenesis in the Endoplasmic Reticulum," (2000) J. Virol., 74(1): pp. 564-72. | |
| | A56 | DE FRANCESCO et al., "Biochemical and immunologic properties of the nonstructural proteins of the hepatitis C virus: implications for development of antiviral agents and vaccines," Semin. Liver Dis., 2000, 20(1):69-83, one page Abstract only. | |
| | A57 | DI BISCEGLIE, Adrian M., "Hepatitis C and Hepatocellular Carcinoma," Hepatology, September 1997, 26(3)Suppl. 1:345-350. | |
| | A58 | DOONG et al., "Inhibition of the replication of hepatitis B virus <i>in vitro</i> by 2',3'-dideoxy-3'-thiacytidine and related analogues," PNAS, October 1991, 88:8495-8499. | |
| | A59 | DUFF et al., "The Transmembrane Domain of Influenza A M2 Protein Forms Amantadine-Sensitive Proton Channels in Planar Lipid Blayers," Virology 190, pp. 485-489 (1992) 0042-6822/92 Copyright 1992 by Academic Press, Inc. | |
| | A60 | DURANTEL et al., "Study of the Mechanism of Antiviral Action of Iminosugars Derivatives against Bovine Viral Diarrhea Virus," (2001) J. Virol. 75(19): pp. 8987-98. | |
| | A61 | DWEK, et al., "Targeting Glycosylation as a Therapeutic Approach," Nature Reviews/Drug Discovery, Vol. 1, January 2002, pp. 65-75. Glycobiology Institute, Dept. of Biochemistry, University of Oxford, Oxford OX1 3QU, UK. | |
| ↓ | A62 | ELBEIN et al., "Inhibitors of the biosynthesis and processing of N-linked oligosaccharide chains," Ann. Rev. Biochem., 1987, 56:497-534. | |

Examiner Signature

/Kathrien Cruz/

Date Considered

03/26/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this sheet with next communication to applicant. 1 Applicant's unique citation designation number (alpha). 2 See Kinds Codes of USPTO Patent Document at www.uspto.gov or MPEP 801.04. 3 Exam Officer that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | |
|--|---|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | Complete if Known | |
| Date Submitted: November 4, 2008 (use as many sheets as necessary) | | | Application Number | 10/031,145 |
| | | | Filing Date | 8/10/2000 |
| | | | First Named Inventor | Nicole Zitzmann |
| | | | Art Unit | 1617 |
| | | | Examiner Name | Kathrien Ann Cruz |
| Sheet | 4 | of | 6 | Attorney Docket Number |
| 080618-0241 | | | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| /K.C./ | A63 | ESPOSITO et al., "Synthesis of amphiphilic polyhydroxylated pyrrolidones as potential glycosidase inhibitors," Tetrahedron Lett., 1998, 39(36):6543-6546. | |
| | A64 | FISCHER et al., "Amantadine blocks channel activity of the transmembrane segment of the NB protein from influenza B," Eur. Biophys J. (2001) 30: pp. 416-420, DOI 10.1007/s00240100157. | |
| | A65 | FLEET et al., "Enantiospecific synthesis of deoxymannojirimycin, fagomine and 2R,5R-dihydroxymethyl-3R,4R-dihydroxypropanolide from D-glucose," Tetrahedron Letters, 1985, 26(11):1469-1472. | |
| | A66 | FOUREL et al., "The Carbocyclic Analog of 2'-Deoxyguanosine Induces a Prolonged Inhibition of Duck Hepatitis B Virus DNA Synthesis in Primary Hepatocyte Cultures and in the Liver," J. Virol., February 1994, 68(2):1059-1065. | |
| | A67 | GABRIELSON et al., "Synthesis and Antiviral Evaluation of N-Carboxamidine-Substituted Analogues of 1,6-D-Ribofuranosyl-1,2,4-triazole-3-carboxamidine Hydrochloride," J. Med. Chem., 1992, 35:3231-3238. | |
| | A68 | GANEM, D., "Assembly of Hepadnaviral Virions and Subviral Particles," Curr. Top. Microbiol. Immunol., 1991, 168:61-83. | |
| | A69 | GRIFFIN et al., "A conserved basic loop in hepatitis C virus p7 protein is required for amantadine-sensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria," Journal of General Virology, 2004, 85:451-461. | |
| | A70 | GRIFFIN et al., "The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine," FEBS Letters 533 (2003) pp. 34-38, Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies. | |
| | A71 | GUIDOTTI et al., "Interleukin-2 and Alpha/Beta Interferon Down-Regulate Hepatitis B Virus Gene Expression In Vivo by Tumor Necrosis Factor-Dependent and -Independent Pathways," J. Virol., March 1994, 68(3):1265-1270. | |
| | A72 | HARADA et al., "E2-p7 Region of the Bovine Viral Diarrhea Virus Polyprotein: Processing and Functional Studies," (2000) J. Virol. 74(20): pp. 9498-506. | |
| | A73 | HAY et al., "The molecular basis of the specific anti-influenza action of amantadine," EMBO Journal, Vol. 4 no. 11 pp. 3021-3024, 1985. 'Oxford, England. | |
| | A74 | HENZLER et al., "Avoiding viral contamination in biotechnological and pharmaceutical processes," Nature Biotechnology, November 1998, 16:1077-1078. | |
| ✓ | A75 | HOOFNAGLE et al., "The Treatment of Chronic Viral Hepatitis," New Engl. J. Med., January 30, 1997, 336(5):347-356. | |

| | | | |
|--------------------|-----------------|-----------------|------------|
| Examiner Signature | /Kathrien Cruz/ | Date Considered | 03/26/2009 |
|--------------------|-----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov. MPEP 801.04, 3 Entity Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

Date Submitted: November 4, 2008
 (use as many sheets as necessary)

Sheet

5

of

6

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/031,145 |
| Filing Date | 8/10/2000 |
| First Named Inventor | Nicole Zitzmann |
| Art Unit | 1617 |
| Examiner Name | Kathrien Ann Cruz |
| Attorney Docket Number | 080618-0241 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| /K.C./ | A76 | LIN et al., "Processing in the Hepatitis C Virus E2-NS2 Region: Identification of p7 and Two Distinct E2-Specific Products with Different C Termini," (1994) J. Virol. 68(8): pp. 5063-73. | |
| | A77 | LOCARNINI et al., "Hepatitis B: New approaches for antiviral chemotherapy," Antiviral Chemistry & Chemotherapy, 1996, 7(2):53-64. | |
| | A78 | LOHMANN et al., "Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line," (1999) Science, 285(5424) pp. 110-3. | |
| | A79 | LU et al., "Aberrant trafficking of hepatitis B virus glycoproteins in cells in which N-glycan processing is inhibited," PNAS, March 1997, 94:2380-2385. | |
| | A80 | MARTIN et al., "Pilot Study of Recombinant Human Granulocyte-macrophage Colony-stimulating Factor in the Treatment of Chronic Hepatitis B," Hepatology, October 1993, 18(4):778-780. | |
| | A81 | MEHTA et al., "a-Glucosidase inhibitors as potential broad based anti-viral agents," FEBS Lett. 1998 June 23; 430(1-2); pp. 17-22. | |
| | A82 | MEHTA et al., "Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitive to glycan processing: Evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion," PNAS, March 1997, 94:1822-1827. | |
| | A83 | MILLER et al., "Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups," PNAS, March 1990, 87:2057-2061. | |
| | A84 | MIZUSHIMA et al., "Two Hepatitis C Virus Glycoprotein E2 Products with Different C Termini," (1994) J. Virol. 68(10); pp. 6215-22. | |
| | A85 | MONTAL et al., "Formation of Bimolecular Membranes from Lipid Monolayers and a Study of Their Electrical Properties," Proc. Nat. Acad. Sci. USA 69 (1972) pp. 3561-3566. | |
| | A86 | PAVLOVIC et al., "The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives," PNAS 2003, May 13; 100(10): pp. 6104-8. | |
| | A87 | PETERSON et al., "Transient, Lectin-like Association of Calreticulin with Folding Intermediates of Cellular and Viral Glycoproteins," Molecular Biology of the Cell, Vol. 6, pp. 1173-1184, September 1995 by The American Society for Cell Biology. | |
| ↓ | A88 | PIETSCHMANN et al., "Characterization of Cell Lines Carrying Self-Replicating Hepatitis C Virus RNAs," (2001) J. Virol. 75(3); pp. 1252-64. | |

Examiner Signature

/Kathrien Cruz/

Date Considered

03/26/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov MPEP 601.04, 3 Entry Office that issued the document, by its two-letter code (WIPO Standard ST.1). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: November 4, 2008

(use as many sheets as necessary)

Complete if Known

| | |
|----------------------|-------------------|
| Application Number | 10/031,145 |
| Filing Date | 8/10/2000 |
| First Named Inventor | Nicole Zitzmann |
| Art Unit | 1617 |
| Examiner Name | Kathrien Ann Cruz |

Sheet

6

of

6

Attorney Docket Number

080618-0241

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁴ |
|--------------------|-----------------------|--|----------------|
| /K.C./ | A89 | REED et al., "Overview of Hepatitis C Virus Genome Structure, Polyprotein Processing, and Protein Properties," Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, pp. 55-84. | |
| | A90 | ROKITSKAYA et al., "Effect of Avidin on Channel Kinetics of Biotinylated Gramicidin," Biochemistry, 2000, 39:13053-13058. | |
| | A91 | SAKAI et al., "The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences," PNAS, September 30, 2003, 100(20):11646-11651. | |
| | A92 | SAUNIER et al., "Inhibition of N-linked Complex Oligosaccharide Formation by 1-Deoxynojirimycin, and Inhibitor of Processing Glucosidases," J. Biol. Chem., December 1982, 257(23):14155-14161. | |
| | A93 | SMITH JP, "Treatment of chronic hepatitis C with amantadine," Dig. Dis. Sci., August 1997, 42(8):1681-1687, one page Abstract only. | |
| | A94 | SULLIVAN et al., "A nested polymerase chain reaction assay to differentiate pestiviruses," Virus Res., 1995, 38:231-239. | |
| | A95 | SUNSTRÖM, et al., "Ion Channels Formed by NB, an Influenza B Virus Protein," J. Membrane Biol. 150, pp. 127-132 (1996). | |
| | A96 | SWARTZ et al., "An Inhibitor of the Kv2.1 Potassium Channel Isolated from the Venom of a Chilean Tarantula," Neuron, October 1996, 15:941-948. | |
| | A97 | VAN DEN BROEK et al., "Chemical modification of azasugars, inhibitors of N-glycoprotein-processing glycosidases and of HIV-1 infection," Recd. Trav. Chim. Pays-Bas, 1993, 112:82-94. | |
| | A98 | WU et al., "Antiviral Effects of an Iminosugar Derivative on Flavivirus Infections," (2002) J. Virol., 76(8): pp. 3598-3604. | |
| | A99 | XU et al., "Synthesis of a novel hepatitis C virus protein by ribosomal frameshift," (2001) The EMBO Journal 20(14): pp. 3840-8. | |
| ▼ | A100 | ZITZMANN, et al., "Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: Implications for the development of broad spectrum anti-hepatitis virus agents," PNAS, Oct. 12, 1991, 88(21):11878-11882. | |

Examiner Signature

/Kathrien Cruz/

Date Considered

03/26/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov MPEP 601.04, 3 Entry Officer who issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.